Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept

Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept 
WINNERSH, UNITED KINGDOM -- (Marketwired) -- 04/29/14 --  Vernalis
plc (LSE: VER) (PINKSHEETS: VNLPY)  
Vernalis plc and Tris Pharma, Inc. today announce the achievement of
proof-of-concept (POC) for CCP-07, the second programme to achieve
this milestone in their US prescription cough cold collaboration.
Under this collaboration, POC requires the successful completion of
several activities, including a successful human pilot comparative
study against an immediate release reference product. Assuming
continued success, an NDA for CCP-07 is expected to be filed in the
second half of 2015. As a result of achieving POC, Vernalis will make
a milestone payment to Tris. 
Under the deal announced in February 2012,Vernalis is paying Tris to
develop up to six unique OralXR+(TM) based extended release liquid
equivalents to existing immediate release prescription cough/cold
treatments. The financial terms of this licensing deal are not
disclosed. 
Ian Garland, CEO of Vernalis commented "CCP-07 is the second of five
programmes currently in development under our collaboration with Tris
to achieve proof-of-concept, with the most advanced, CCP-01, on-track
for NDA filing in the middle of this year. We are delighted with the
continuing progress of our pipeline of cough cold programmes and look
forward to further successes over the remainder of 2014". 
Ketan Mehta, CEO of Tris commented "Tris is excited with the
continued progress of the prescription cough/cold portfolio. The
products are a great application of our OralXR+(TM) technology and
will ultimately improve patient care". 
Notes to Editors 
About Vernalis 
Vernalis is a revenue generating development stage pharmaceutical
company with significant expertise in drug development. The Group has
one marketed product, frovatriptan for the acute treatment of
migraine, an exclusive licensing agreement to develop and
commercialise multiple novel products focussed on the US prescription
cough cold market as well as seven programmes in its NCE development
pipeline. Vernalis has also significant expertise in fragment and
structure based drug discovery which it leverages to enter into
collaborations with larger pharmaceutical companies. The Company's
technologies, capabilities and products have been endorsed over the
last five years by collaborations with leading pharmaceutical
companies, including AKP, Biogen Idec, Endo, GSK, Genentech,
Lundbeck, Menarini, Novartis, Servier and Tris. 
For further information about Vernalis, please visit www.vernalis.com 
About Tris Pharma 
Tris Pharma is a specialty pharmaceutical company focused on the
research and development of technologies-driven products. Tris has
pioneered the delivery of sustained release in the liquid,
chewable/ODT and strip dosage forms so patients do not have to
swallow a pill. Tris' Nobuse(TM) technology provides abuse deterrence
for opioids and other abuse-prone drugs. Tris' R&D and manufacturing
facilities are located in Monmouth Junction, New Jersey, U.S.A. 
For more information, please visit www.trispharma.com 
Vernalis Forward-Looking Statement 
This news release may contain forward-looking statements that reflect
the Company's current expectations regarding future events including
the clinical development and regulatory clearance of the Company's
products, the Company's ability to find partners for the development
and commercialisation of its products, as well as the Company's
future capital raising activities. Forward-looking statements involve
risks and uncertainties. Actual events could differ materially from
those projected herein and depend on a number of factors including
the success of the Company's research strategies, the applicability
of the discoveries made therein, the successful and timely completion
of clinical studies, the uncertainties related to the regulatory
process, the ability of the Company to identify and agree beneficial
terms with suitable partners for the commercialisation and/or
development of its products, as well as the achievement of expected
synergies from such transactions, the acceptance of frovatriptan and
other products by consumers and medical professionals, the successful
integration of completed mergers and acquisitions and achievement of
expected synergies from such transactions, and the ability of the
Company to identify and consummate suitable strategic and business
combination transactions. 
This information is provided by RNS
 The company news service from
the London Stock Exchange 
Enquiries: 
Vernalis plc:
+44 (0) 118 938 0015
Ian Garland
Chief Executive Officer 
David Mackney
Chief Financial Officer 
Tris Pharma, Inc.: 
+1 732 940 2800 x104
Peter Ciano
SVP, Strategy and Corporate Development 
Canaccord Genuity Limited (Nominated Adviser): 
+44 (0) 20 7523 8350
Lucy Tilley
Dr Julian Feneley
Henry Fitzgerald-O'Connor 
Shore Capital (Joint Broker): 
+44 (0)20 7408 4090
Bidhi Bhoma
Toby Gibbs 
Brunswick Group: 
+44 (0) 20 7404 5959
Jon Coles 
 
 
Press spacebar to pause and continue. Press esc to stop.